Feb 27 |
Manuscript Discussing the Benefit of SeaStar Medical’s Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure
|
Feb 22 |
Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™
|
Feb 22 |
FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical’s Selective Cytopheretic Device for Pediatric Acute Kidney Injury
|
Feb 15 |
Looking Into SeaStar Medical Holding's Recent Short Interest
|
Feb 1 |
SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device Technology
|
Jan 26 |
SeaStar Medical announces pricing of $9M registered direct offering
|
Jan 26 |
SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market
|
Jan 24 |
SeaStar Medical files to sell 8.25M shares for its holders
|
Jan 12 |
Citigroup, Bank of America And 3 Stocks To Watch Heading Into Friday
|
Jan 11 |
SeaStar Medical appoints David Green as CFO
|